< Back to previous page
Project
ThermoBreast : An innovative non-contact and harmless screening modality set to change the course of breast cancer detection and patient monitoring (EUAR122)
Female breast cancer is the most diagnosed cancer worldwide. In 2020, the International Agency for Research on Cancer estimated
more than 2.26 million new cases of breast cancer. Early detection is crucial to survival; recovery rates approach 90% when detected
in early stages. National population-based cancer screening programmes in Europe currently implement 3 standard imaging
modalities: mammography, ultrasound and MRI. The downsides of these screening methods include ionising radiation, high costs and
high false positive rates in screening results.
Our multidisciplinary consortium of 16 partners from 10 countries aims to contribute to EU’s Mission on Cancer and Beating Cancer
Plan by drastically improving the prevention, diagnosis and monitoring of breast cancer while reducing the burden on women and
female patients and their families, health care professionals and others who are directly or indirectly affected by breast cancer.
ThermoBreast proposes a new solution for accurate, harmless and non-contact screening, equally applicable for all age groups and
breast densities and capable of detecting pre-cancerous states. This risk-free screening technology, recently patented by the project
coordinator ThermoMind LTD, can detect vascular anomalies and asymmetry, caused by cancerous growth. It combines innovative
screening through multiple sensitive infrared sensors with advanced AI analysis of temporal dynamic thermal patterns
more than 2.26 million new cases of breast cancer. Early detection is crucial to survival; recovery rates approach 90% when detected
in early stages. National population-based cancer screening programmes in Europe currently implement 3 standard imaging
modalities: mammography, ultrasound and MRI. The downsides of these screening methods include ionising radiation, high costs and
high false positive rates in screening results.
Our multidisciplinary consortium of 16 partners from 10 countries aims to contribute to EU’s Mission on Cancer and Beating Cancer
Plan by drastically improving the prevention, diagnosis and monitoring of breast cancer while reducing the burden on women and
female patients and their families, health care professionals and others who are directly or indirectly affected by breast cancer.
ThermoBreast proposes a new solution for accurate, harmless and non-contact screening, equally applicable for all age groups and
breast densities and capable of detecting pre-cancerous states. This risk-free screening technology, recently patented by the project
coordinator ThermoMind LTD, can detect vascular anomalies and asymmetry, caused by cancerous growth. It combines innovative
screening through multiple sensitive infrared sensors with advanced AI analysis of temporal dynamic thermal patterns
Date:1 Jan 2023 → Today
Keywords:Screening programme, Clinical analysis, Cost efficiency, Diagnostic technology, Disease prevention, Personalised prevention
Disciplines:Cancer diagnosis
Project type:Collaboration project